| Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C] pyruvate SJ Nelson, J Kurhanewicz, DB Vigneron, PEZ Larson, AL Harzstark, ... Science translational medicine 5 (198), 198ra108-198ra108, 2013 | 1361 | 2013 |
| KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ... New England Journal of Medicine 383 (13), 1207-1217, 2020 | 1286 | 2020 |
| Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma AI Daud, RC DeConti, S Andrews, P Urbas, AI Riker, VK Sondak, ... Journal of clinical oncology 26 (36), 5896, 2008 | 844 | 2008 |
| 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts DB Solit, FF Zheng, M Drobnjak, PN Münster, B Higgins, D Verbel, ... Clinical cancer research 8 (5), 986-993, 2002 | 559 | 2002 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells PN Munster, T Troso-Sandoval, N Rosen, R Rifkind, PA Marks, ... Cancer research 61 (23), 8492-8497, 2001 | 480 | 2001 |
| Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC PC Tumeh, MD Hellmann, O Hamid, KK Tsai, KL Loo, MA Gubens, ... Cancer immunology research 5 (5), 417-424, 2017 | 442 | 2017 |
| Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen … DA Yardley, RR Ismail-Khan, B Melichar, M Lichinitser, PN Munster, ... Journal of Clinical Oncology 31 (17), 2128, 2013 | 438 | 2013 |
| A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer PN Munster, KT Thurn, S Thomas, P Raha, M Lacevic, A Miller, M Melisko, ... British journal of cancer 104 (12), 1828-1835, 2011 | 430 | 2011 |
| Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ... JAMA oncology 5 (8), 1141-1149, 2019 | 411 | 2019 |
| A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors KK Wong, PM Fracasso, RM Bukowski, TJ Lynch, PN Munster, GI Shapiro, ... Clinical cancer research 15 (7), 2552-2558, 2009 | 382 | 2009 |
| A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells G Chiosis, MN Timaul, B Lucas, PN Munster, FF Zheng, L Sepp-Lorenzino, ... Chemistry & biology 8 (3), 289-299, 2001 | 363 | 2001 |
| Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic … M Lambertini, HCF Moore, RCF Leonard, S Loibl, P Munster, M Bruzzone, ... Journal of clinical oncology 36 (19), 1981, 2018 | 334 | 2018 |
| 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response … H Lee, AF Shields, BA Siegel, KD Miller, I Krop, CX Ma, PM LoRusso, ... Clinical Cancer Research 23 (15), 4190-4202, 2017 | 323 | 2017 |
| Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 AD Basso, DB Solit, PN Munster, N Rosen Oncogene 21 (8), 1159-1166, 2002 | 323 | 2002 |
| Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer KT Thurn, S Thomas, A Moore, PN Munster Future oncology 7 (2), 263-283, 2011 | 301 | 2011 |
| Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo) adjuvant chemotherapy for breast cancer PN Munster, AP Moore, R Ismail-Khan, CE Cox, M Lacevic, M Gross-King, ... Journal of Clinical Oncology 30 (5), 533, 2012 | 294 | 2012 |
| Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas OA Zill, C Greene, D Sebisanovic, LM Siew, J Leng, M Vu, AE Hendifar, ... Cancer discovery 5 (10), 1040-1048, 2015 | 273 | 2015 |
| Discussion of fertility preservation with newly diagnosed patients: oncologists’ views GP Quinn, ST Vadaparampil, CK Gwede, C Miree, LM King, HB Clayton, ... Journal of cancer survivorship 1, 146-155, 2007 | 267 | 2007 |
| Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study P Münster, D Marchion, E Bicaku, M Schmitt, JH Lee, R DeConti, ... Journal of Clinical Oncology 25 (15), 1979-1985, 2007 | 266 | 2007 |
| Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal PA Ott, SA Piha-Paul, P Munster, MJ Pishvaian, EMJ Van Brummelen, ... Annals of Oncology 28 (5), 1036-1041, 2017 | 258 | 2017 |
Adil DaudProfessor of Medicine, University of California, San FranciscoVerified email at ucsf.edu
